Showing results (141-150 of 154) with videos related to
Sort By:
Pageof 16
Oncotarget|May 21, 2016
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse modelsMimma Bianco, Anna Gasparri, Luca Generoso, et al.Intensive Care Medicine|June 19, 2012
Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significanceFrancis Schneider, Charlotte Bach, Hélène Chung, et al.The Journal of Endocrinology|November 2, 2016
Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout miceKechun Tang, Teresa Pasqua, Angshuman Biswas, et al.Acta Physiologica (Oxford, England)|October 19, 2020
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1Carmine Rocca, Fedora Grande, Maria Concetta Granieri, et al.Regulatory Peptides|December 28, 2010
Processing of chromogranins/secretogranin in patients with diabetic retinopathyIsabelle Fournier, David Gaucher, Jean-F Chich, et al.Methods in Enzymology|November 17, 2009
Liposome-mediated therapy of neuroblastomaDaniela Di Paolo, Monica Loi, Fabio Pastorino, et al.Cell and Tissue Research|February 22, 2017
Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretionJoshua Wollam, Sumana Mahata, Matthew Riopel, et al.Journal of Leukocyte Biology|October 4, 2008
Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activationGabriele Di Comite, Carlo M Rossi, Alessandro Marinosci, et al.Cell and Tissue Research|November 24, 2018
Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic (PACAPergic) stimulation in PC12 cellsBhavani Shankar Sahu, Sumana Mahata, Keya Bandyopadhyay, et al.European Journal of Cancer (Oxford, England : 1990)|November 11, 2009
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursVanesa Gregorc, Giovanni Citterio, Giordano Vitali, et al.Pageof 16